Amneal Pharmaceuticals develops, manufactures and commercializes generic and specialty medicines, with a broad U.S. generics portfolio plus select branded, injectable and biosimilar-related products. It operates manufacturing and R&D capacity aimed at complex dosage forms as well as high-volume oral solids. Customers include wholesalers, pharmacies, hospitals and other channels that supply affordable prescription alternatives.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 724.5 | — | 22.4 | — |
| Q3 2025 | 784.5 | — | 2.4 | — |
| Q4 2025 | 814.3 | — | 35.1 | — |
| Q1 2026 | 722.5 | — | 62.3 | — |
| Q2 2026 | 796.2 | 9.9% | 57.7 | 157.2% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Victory Capital Holdings, Inc. (VCTR), Duolingo, Inc. (DUOL), Navan, Inc. (NAVN), SSR Mining Inc. (SSRM), NICE Ltd. (NICE), Global-E Online Ltd. (GLBE)